Home  >  Investors  >  Investor Resources  >  Financial Tear Sheet

Financial Tear Sheet

Corporate Profile

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 35,000 products in nearly every therapeutic area. 200 million people around the world take a Teva medicine every day, served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

Primary IR Contact
Investor Relations
Phone: (215) 591-3034
E-mail: ir@tevapharm.com

SEC Filings

Date Filing Type Filing Description Download / View

Financial Reports


Corporate Officers

Kåre Schultz
President and CEO

Iris Beck-Codner
Executive Vice President, Global Brand & Communications

Richard Daniell
Executive Vice President, European Commercial

Sven Dethlefs
Executive Vice President, Global Marketing & Portfolio

Dr. Hafrun Fridriksdottir
Executive Vice President, Global R&D

Michael (Mike) McClellan
Executive Vice President, Chief Financial Officer

Gianfranco Nazzi
Executive Vice President, Growth Markets Commercial

Dr. Carlo de Notaristefani
Executive Vice President, Global Operations

Brendan O'Grady
Executive Vice President, North America Commercial

Mark Sabag
Group Executive Vice President, Human Resources

David M. Stark
Group Executive Vice President, Chief Legal Officer

Nir Baron
Executive Vice President, Chief Internal Auditor